CORRESP Filing
Wellgistics Health, Inc.
Date: Aug. 28, 2025 · CIK: 0002030763 · Accession: 0001641172-25-025831
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288932
Letter
Division of Corporate Finance Office of Trade & Services F Street, N.E. Washington, D.C. 20549 Attention: Nicholas Nalbantian Re: Wellgistics Health, Inc. Registration Statement on Form S-1 Filed July 24, 2025 File No. 333-288932
Dear Mr. Nalbantian:
This response letter (this " Response ") is submitted on behalf of Wellgistics Health, Inc. (the " Company ") in response to the comments that the Company received from the staff of the Division of Corporation Finance (the " Staff ") of the U.S. Securities and Exchange Commission (the " SEC ") in a letter addressed to Mr. Norton, dated August 8, 2025 (the " Comment Letter "), with respect to the Company's Registration Statement on Form S-1 (the " Registration Statement "), filed with the SEC on July 24, 2025. The Company is concurrently submitting the first amendment to the Registration Statement (" Amendment No. 1 ").
For reference purposes, each of the Staff's numbered comments from the Comment Letter is set forth in bold text below, followed by the Company's response to each comment. The responses below are based on information provided to Dykema Gossett PLLC by the Company.
Registration Statement on Form S-1
Use of Proceeds, page 11
1. We note the disclosure surrounding your planned XRP Treasury Strategy and its execution in "the near future." If you intend on using the proceeds of this offering to purchase XRP to further your XRP Treasury Strategy, please disclose as much in this section. Refer to Instruction 5 to Item 504 of Regulation S-K.
Response : In response the Staff's comment, the Company respectfully advises the Staff that the Company does not intend on using the proceeds of this offering to purchase XRP.
California | Illinois | Michigan | Minnesota | Texas | Washington, D.C. | Wisconsin
U.S. Securities and Exchange Commission
Division of Corporate Finance
August 28, 2025
Page
2. We note the disclosure surrounding your planned acquisition of Peek Healthcare Technologies, Inc. If you intend on using the proceeds of this offering to finance the acquisition of Peek Healthcare Technologies, Inc., please disclose as much in this section. Refer to Instruction 6 to Item 504 of Regulation S-K.
Response : In response the Staff's comment, the Company respectfully advises the Staff that the Company does not intend on using the proceeds of this offering to finance the Company's acquisition of Peek Healthcare Technologies, Inc..
* * *
Thank you for your review and consideration of the matters set forth in this Response and in Amendment No. 1. If you have any questions, please contact the undersigned at (414) 488-7333 or KBechen@dykema.com.
Sincerely,
Dykema
Gossett PLLC
Show Raw Text
CORRESP
1
filename1.htm
Dykema
Gossett PLLC
111
E. Kilbourn Ave.
Suite
1050
Milwaukee,
WI 53202
www.dykema.com
Tel:
414-488-7300
Kate
Bechen
Direct
Dial: (414) 488-7333
Email:
KBechen@dykema.com
August
28, 2025
U.S.
Securities and Exchange Commission
Division
of Corporate Finance
Office
of Trade & Services
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Nicholas Nalbantian
Re:
Wellgistics
Health, Inc.
Registration
Statement on Form S-1
Filed
July 24, 2025
File
No. 333-288932
Dear
Mr. Nalbantian:
This
response letter (this " Response ") is submitted on behalf of Wellgistics Health, Inc. (the " Company ")
in response to the comments that the Company received from the staff of the Division of Corporation Finance (the " Staff ")
of the U.S. Securities and Exchange Commission (the " SEC ") in a letter addressed to Mr. Norton, dated August 8, 2025
(the " Comment Letter "), with respect to the Company's Registration Statement on Form S-1 (the " Registration
Statement "), filed with the SEC on July 24, 2025. The Company is concurrently submitting the first amendment to the Registration
Statement (" Amendment No. 1 ").
For
reference purposes, each of the Staff's numbered comments from the Comment Letter is set forth in bold text below, followed by
the Company's response to each comment. The responses below are based on information provided to Dykema Gossett PLLC by the Company.
Registration
Statement on Form S-1
Use
of Proceeds, page 11
1.
We
note the disclosure surrounding your planned XRP Treasury Strategy and its execution in "the near future." If you intend
on using the proceeds of this offering to purchase XRP to further your XRP Treasury Strategy, please disclose as much in this section.
Refer to Instruction 5 to Item 504 of Regulation S-K.
Response :
In response the Staff's comment, the Company respectfully advises the Staff that the Company does not intend on using the proceeds
of this offering to purchase XRP.
California
| Illinois | Michigan | Minnesota | Texas | Washington, D.C. | Wisconsin
U.S.
Securities and Exchange Commission
Division
of Corporate Finance
August
28, 2025
Page
2
2.
We
note the disclosure surrounding your planned acquisition of Peek Healthcare Technologies, Inc. If you intend on using the proceeds
of this offering to finance the acquisition of Peek Healthcare Technologies, Inc., please disclose as much in this section. Refer
to Instruction 6 to Item 504 of Regulation S-K.
Response :
In response the Staff's comment, the Company respectfully advises the Staff that the Company does not intend on using the proceeds
of this offering to finance the Company's acquisition of Peek Healthcare Technologies, Inc..
*
* *
Thank
you for your review and consideration of the matters set forth in this Response and in Amendment No. 1. If you have any questions, please
contact the undersigned at (414) 488-7333 or KBechen@dykema.com.
Sincerely,
Dykema
Gossett PLLC
/s/
Kate Bechen
Kate
Bechen, Esq.
cc:
Brian
Norton
Chief
Executive Officer
Wellgistics
Health, Inc.